412293-87-9

Usage

Uses

Used in Organic Synthesis:
1-Boc-4-butylpiperazine is used as a reagent for the modification of various organic molecules, leveraging its unique structure and functional groups to facilitate the synthesis of complex organic compounds.
Used in Pharmaceutical Research:
1-Boc-4-butylpiperazine is used as a building block in the development of new drugs and pharmaceuticals, particularly in the creation of molecules targeting the central nervous system and other therapeutic areas, due to its potential applications in medicinal chemistry.
Used in Drug Development:
1-Boc-4-butylpiperazine is utilized as a key component in the design and synthesis of innovative drug candidates, contributing to the advancement of pharmaceuticals with improved efficacy and selectivity in treating various medical conditions.

InChI:InChI=1/C13H26N2O2/c1-5-6-7-14-8-10-15(11-9-14)12(16)17-13(2,3)4/h5-11H2,1-4H3

Upstream product

• 123-72-8 butyraldehyde 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 109-65-9 1-bromo-butane 

Downstream Products

• 174358-28-2 PD 161654 

Relevant academic research and scientific papers

Triton B-mediated mild, convenient, and efficient method for the selective alkylation of cyclic secondary amines and thiols

Alkylation of cyclic secondary amines, thiols, and pyridazinones has been demonstrated with alkyl halides using Triton B as base and reaction medium.

PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES

Substituted piperazinyl and diazepanyl benzamides and benzthioamides of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.

Structure-activity relationships of the quinolone antibacterials against mycobacteria: Effect of structural changes at N-1 and C-7

The re-emergence of tuberculosis infections which are resistant to conventional drug therapy has demonstrated the need for alternative chemotherapy against Mycobacterium tuberculosis. As part of a study to optimize the quinolone antibacterials against M. tuberculosis, we have prepared a series of N-1- and C-7-substituted quinolones to examine specific structure-activity relationships between modifications of the quinolone at these two positions and activity against mycobacteria. The compounds, synthesized by literature procedures, were evaluated for activity against Mycobacterium fortuitum and Mycobacterium smegmatis as well as Gram-negative and Gram-positive bacteria. The activity of the compounds against M. fortuitum was used as a barometer of M. tuberculosis activity. The results demonstrate that (i) the activity against mycobacteria was related more to antibacterial activity than to changes in the lipophilicity of the compounds, (ii) the antimycobacterial activity imparted by the N-1 substituent was in the order tert-butyl ≥ cyclopropyl > 2,4-difluorophenyl > ethyl ? cyclobutyl > isopropyl, and (iii) substitution with either piperazine or pyrrolidine heterocycles at C-7 afforded similar activity against mycobacteria.